Nine Catalysts For China Biopharma In 2019
Executive Summary
After much turmoil in 2018, the biopharma sector in China is embracing multiple uncertainties in the year of the boar.
You may also be interested in...
China Releases List To Encourage Competition
China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.
Bring Them On: China Releases Generics List To Encourage Competition
China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.
China - The Next Promised Land For Korean Biosimilars?
Biosimilar specialists Celltrion and Samsung Bioepis are poised to start competing in China, which they see as another promising market for their biosimilars amid the Chinese government's increasing policy support for biologics and generics, and rising competition elsewhere. Part of their tailored entry approach includes striking deals with local partners.